Avalo Therapeutics (AVTX) Short-term Investments (2019 - 2026)

Avalo Therapeutics (AVTX) posted Short-term Investments of $57.0 million for Q1 2026, down 30.88% on a QoQ basis from $82.5 million in Q4 2025.

Avalo Therapeutics (AVTX) Short-term Investments (2019 - 2026) Analysis & Trends

Avalo Therapeutics' Short-term Investments history runs 4 years deep, the most recent figure standing at $57.0 million for Q1 2026.

Quarterly Short-term Investments changed N/A year-over-year to $57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.0 million (changed N/A YoY) and the FY2025 annual result came in at $82.5 million, changed N/A from the prior year.
Short-term Investments was $57.0 million for Q1 2026 at Avalo Therapeutics, down from $82.5 million in the prior quarter.
Across five years, Short-term Investments topped out at $84.7 million in Q3 2025 and bottomed at $57.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Avalo Therapeutics	1.04 Mn	1.04 Mn	-

Download Data